The FDA has approved Servier's VORANIGO® (vorasidenib) tablets as the first targeted treatment for Grade 2 IDH-mutant glioma.

NeuroBo Pharmaceuticals, Dong-A ST, and ImmunoForge Sign Agreement to Collaborate on Developing a Monthly DA-1726 Formulation to Treat Obesity.

The initial participant in the U.S. joins the phase III global multi-center clinical trial for telitacicept targeting myasthenia gravis, marking a significant milestone.

Elevation Oncology Releases Encouraging Early Results from Phase 1 Trial of EO-3021 in Patients with Advanced Non-Resectable or Metastatic Solid Tumors.

This expansion now encompasses Merck’s investigational product MK-6070, a T-cell engager targeting delta-like ligand 3 (DLL3).

Equillium Reports Favorable Interim Results from Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease.

Global pharma major Lupin Limited, revealed the introduction of its first biosimilar in Canada, Rymti®, via its collaborator, Sandoz Canada.

Global Pharma major Lupin Limited revealed the completion of an international Phase 3 clinical trial for its biosimilar LUBT010.

Levicept Reveals Successful Phase II Trial Results for LEVI-04, a Novel Neurotrophin-3 Inhibitor, in Treating Moderate to Severe Osteoarthritis.

First Patient Enrolled in US Phase 2 Trial of Akeso’s Ligufalimab and Azacitidine Combo for Myelodysplastic Syndrome.

Genmab A/S revealed that it will take over full responsibilities for both the ongoing development and possible commercialization of acasunlimab.

Rezolute Receives FDA Approval for Phase 3 IND Study of RZ358 for Hypoglycemia Caused by Tumor-Induced Hyperinsulinism.